ShockWave Medical, Inc. SWAV NASDAQ

ShockWave Medical, Inc. (SWAV) generated $196.05M in operating cash flow for fiscal year 2023. After capital expenditures of $30.6M, free cash flow was $165.46M.

Free cash flow margin was 22.7% of revenue. Cash conversion ratio was 1.33x, indicating earnings are backed by cash.

The company returned $43K in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (76/100, Pass) — $165.46M (22.7% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 1.33x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 60/100 with 4/7 criteria passed.